FCAG
PASG icon

First Capital Advisors Group’s Passage Bio PASG Stock Holding History

First Capital Advisors Group’s Portfolio PASG Stock Details PASG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$22 Buy
+1
New +$20 ﹤0.01% 964

Other funds holding PASG

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

First Capital Advisors Group's PASG Position: Q2 2023 in Review

First Capital Advisors Group opened a new position in Passage Bio (PASG) in Q2 2023: 1 share worth $22. The stake represents ﹤0.01% of the portfolio and ranks #964 among its holdings.

54 funds tracked by Wall St. Rank hold PASG as of Q2 2023.

  • First Capital Advisors Group held 1 share of Passage Bio worth $22 as of Q2 2023.
  • Passage Bio was a new First Capital Advisors Group position in Q2 2023.
  • Passage Bio made up ﹤0.01% of First Capital Advisors Group's portfolio in Q2 2023, its #964 holding.
  • 54 funds tracked by Wall St. Rank held Passage Bio as of Q2 2023.

Based on First Capital Advisors Group's 13F filing for Q2 2023, filed 15 Aug 2023.